[Prognostic significance of serum immunoglobulin paraprotein in chronic lymphocytic leukemia]
Related Experiment Video
Updated: May 14, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Shu Yang1, Zhi-jian Zou, Yuan-yuan Li
1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Insights
Serum immunoglobulin paraprotein is found in approximately 20% of chronic lymphocytic leukemia (CLL) patients. Its presence, particularly IgM paraprotein, is associated with shorter treatment-free survival, suggesting prognostic value in CLL management.
Area of Science:
- Hematology
- Immunology
- Oncology
Context:
- Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
- Serum immunoglobulin (Ig) paraproteins are abnormal proteins produced by malignant B-cells.
- The clinical significance of paraproteins in CLL requires further elucidation.
Purpose:
- To determine the incidence of serum Ig paraprotein in CLL patients.
- To identify clinical and laboratory features associated with paraprotein presence.
- To evaluate the prognostic impact of serum Ig paraprotein on treatment-free survival (TFS).
Summary:
- Serum protein and immunofixation electrophoresis identified Ig paraprotein in 19.8% of 101 CLL patients.
- IgG paraprotein correlated with advanced Binet stage and high thymidine kinase 1 (TK1).
- IgM paraprotein associated with advanced Binet stage, high TK1, and del(11q22.3) cytogenetic abnormality.
- Patients with serum Ig paraprotein, especially IgM, exhibited significantly shorter TFS.
- However, serum Ig paraprotein was not an independent prognostic factor.
Impact:
- This study highlights the prevalence of serum Ig paraprotein in CLL.
- Findings suggest that paraprotein detection may aid in risk stratification.
- Further research is warranted to integrate paraprotein analysis into CLL prognostic models.
Objective:
To investigate the incidence of serum immunoglobulin (Ig) paraprotein in chronic lymphocytic leukemia (CLL), and to explore its clinical associated laboratory features and prognostic implication.
Methods:
Serum protein electrophoresis and immunofixation electrophoresis were performed by automatic electrophoresis apparatus to identify serum Ig paraprotein. Immunonephelometry was used to measure serum Ig levels.
Results:
Out of 101 CLL patients, serum Ig paraprotein detection was found in 20 (19.8%) cases, 13 (12.9%) patients with IgG paraprotein, 7 (6.9%) patients with IgM paraprotein and 1(1.0%) patient with IgA paraprotein. Among these 20 cases, 1 patient had both IgG and IgM paraprotein, 2 patients had both κ and λ light chains. The incidence of serum IgG paraprotein was high in the group of advanced Binet stage (P = 0.032) and high level of thymidine kinase 1 (TK1) (P = 0.013). The incidence of serum IgM paraprotein was high in the group of advanced Binet stage (P = 0.037), high level of TK1 (P = 0.017) and cytogenetic abnormalities of del(11q22.3) (P = 0.006). With a median follow-up of 30 months (range 1 - 101 months), 66 patients received therapy after initial diagnosis. Survival analysis showed that the patients with serum Ig paraprotein had significantly shorter treatment-free survival (TFS) times than the patients without serum Ig paraprotein (P = 0.024). And the patients with serum IgM paraprotein had significantly shorter treatment-free survival (TFS) times than the patients without serum Ig paraprotein (P = 0.013). However, serum Ig paraprotein or IgM paraprotein was not independent prognostic factor.
Conclusion:
Serum Ig paraprotein can be detected in a subset of patients with CLL, which could be of value as a prognostic factor in CLL.
